文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

药师指导的抑郁症抗抑郁药治疗预先行药物基因组学检测(PrePGx):一项开放标签随机对照试验的研究方案

Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial.
PubMed 文献 · Trials · 2021-12-14

本研究为在瑞士两个研究中心开展的开放标签随机对照试验,纳入诊断为单相中度或重度抑郁发作的成人住院患者。当需要调整为新抗抑郁药治疗时,参与者随机分为干预组(药师指导的预先行药物基因组学检测辅助选药和剂量)或对照组(医生按现行指南常规选药且不知晓检测结果),主要结局比较4周后两组应答率;无需新治疗者进入观察臂。

要点

  • 仅50%的抑郁症患者对一线抗抑郁药治疗有应答,需提高应答率。
  • 干预为药师指导的预先行药物基因组学检测,辅助抗抑郁药选择和剂量决策。
  • 主要结局为4周抗抑郁药治疗后的应答率,比较干预组与对照组。

核心结论

  • 该临床试验的发现预计将对精神科实践中药物基因组学数据处理的跨专业协作产生直接影响。

研究设计与样本

  • 开放标签随机对照试验,在瑞士两个研究中心开展:索洛图恩精神病诊所和明兴布赫塞Wyss私立诊所。
  • 招募入院时诊断为单相中度或重度抑郁发作的成人住院患者。
  • 需要调整为新抗抑郁药治疗者随机分为A组(干预组)或B组(对照组);未引入新抗抑郁药治疗者进入观察臂。
  • 干预为药师指导的预先行药物基因组学检测,以支持抗抑郁药选择和剂量的临床决策。
  • 对照组由治疗医生按现行治疗指南选择抗抑郁药治疗(标准治疗),不知晓药物基因组学检测结果且无临床药师支持。

主要发现

  • 主要结局比较干预组与对照组4周抗抑郁药治疗后的应答率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is known that only 50% of patients diagnosed with major depressive disorders (MDD) respond to the first-line antidepressant treatment. Accordingly, there is a need to improve response rates to reduce healthcare costs and patient suffering. One approach to increase rates of treatment response might be the integration of pharmacogenetic (PGx) testing to stratify antidepressant drug selection. The goal of PGx assessments is to identify patients who have an increased risk to experience adverse drug reactions or non-response to specific drugs. Especially for antidepressants, there is compiling evidence on PGx influencing drug exposure as well as response. METHODS: This study is an open-label, randomized controlled trial conducted in two study centers in Switzerland: (1) the Psychiatric Clinic of Solothurn and (2) the Private Clinic Wyss in Münchenbuchsee. Adult inpatients diagnosed with a unipolar moderate or severe depressive episode are recruited at clinic admission and are included in the study. If the adjustment to a new antidepressant pharmacotherapy is necessary, the participants are randomized to either Arm A (intervention group) or Arm B (control group). If no new antidepressant pharmacotherapy is introduced the participants will be followed up in an observational arm. The intervention is the service of pharmacist-guided pre-emptive PGx testing to support clinical decision making on antidepressant selection and dosing. As a comparison, in the control group, the antidepressant pharmacotherapy is selected by the treating physician according to current treatment guidelines (standard of care) without the knowledge of PGx test results and support of clinical pharmacists. The primary outcome of this study compares the response rates under antidepressant treatment after 4 weeks between intervention and control arm. DISCUSSION: The findings from this clinical trial are expected to have a direct impact on inter-professional collaborations for the handling and use of PGx data in psychiatric practice. TRIAL REGISTRATION: ClinicalTrials.gov NCT04507555 . Registered on August 11, 2020. Swiss National Clinical Trials Portal SNCTP000004015 . Registered August 18, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Stäuble CK, Lampert ML, Allemann S, et al. Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial. Trials. 2021. PMID: 34906208. doi:10.1186/s13063-021-05724-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。